Brisbane Veterinary Specialist Centre, in conjunction with Australian company QBiotics Group Limited, have recently completed a clinical trial of tigilanol tiglate (TT) on soft tissue sarcomas (STS).

This study will provide further efficacy and safety data as well as pave the way for safe and appropriate use of this drug on non-metastatic STS tumours.

The study involved 6 dogs, of which 5 had histologically diagnosed Soft Tissue Sarcoma, and 1 was diagnosed with haemangiosarcoma. Complete response was achieved on 4 out of the 5 STS tumours, with either 1 or 2 injections of TT.

The haemangiosarcoma had 3 injections of TT and a partial response, with a marginal resection surgery following the third treatment.